'Slow release L-DOPA analogs LDA and NALDA, for the treatment of Parkinsons disease and other related indications. LDA and NALDA are highly lipophyllic and penetrate the brain very efficiently crossing the cell membrane. This property increases the...

'Slow release L-DOPA analogs LDA and NALDA, for the treatment of Parkinsons disease and other related indications. LDA and NALDA are highly lipophyllic and penetrate the brain very efficiently crossing the cell membrane. This property increases the bioavailability of L-DOPA in the brain, and allows smaller amounts to be used compared to that of L-DOPA. The new carriers become substrates for the aromatic amino acid decarboxylase (AADC) only in vivo. This property could eliminate the use of AADC inhibitor (carbidopa) from the treatment of PD patients. The slow conversion of these carriers in the brain to L-DOPA represents a slow release mode of drug administration. A gradual formation of L-DOPA, would mimic the advantages of a constant and gradual level of dopamine, typical of slow drug medication.'

Novel treatment for Parkinsons disease overcomes "on-off" phenomenon

Categories	Parkinsons disease, L-dopa, L-dopa amide
Development Stage	Concept proven, in vivo human models
Patent Status	Pending patent application in Europe, US and Israel(PCT publication no. WO2004/069146)

 Highlights

• Increases the endogenous level of dopamine to alleviate the motor complications of Parkinsons disease and to delay the onset of the symptoms from the dramatic decrease in dopamine
• Formulated for buccal, oral, sub-lingual, parenteral, intranasal, intramuscular, intravenous, subcutaneous, intraduodenal or rectal administration

 Our Innovation

• Provides a pharmaceutical preparation for the treatment of patients suffering from PD comprising a composition of L-Dopamide
• Involves an essential structural change to make L-DOPA more soluble and resistant to DOPA Decarboxylase
• Administrable without Carbidopa due to resistance to DOPA-decarboxylase
• L-Dopamide is slowly hydrolyzed to L-DOPA because it is resistance to DOPA decarboxylase
• Slow release addresses the on/off phenomenon of Parkinsons
• Degrades to natural products

 The Opportunity

• Addresses the need for more effective therapy for Parkinsons disease using a more sustained level of dopamine

 Development Milestones

• Use of animal models as a proof of concept in experiments made side by side with L-DOPA

 

project-id 7-2006-138

Early Stage

Pending patent application in Europe, US and Israel(PCT publication no. WO2004/069146)